Home|Journals|Articles by Year

Directory for Medical Articles
 

Open Access

Review Article



Tyrosine Kinase Inhibitors; an Approach for Targeted Cancer Therapies-A Review

Arpita Shrivastav, Neeraj Shrivastava.

Abstract
Targeted cancer therapies include drugs which target specific molecules involved in the growth of cancer cells. These therapies include monoclonal antibodies that attack cell surface receptors, apoptosis-inducing drugs, angiogenesis inhibitors and enzyme inhibitors that enter cells and inhibit critical cell enzymes. Tyrosine kinase inhibitors are synthetic agents that inhibit signal transduction pathways and interfere with activation of enzymes tyrosine kinase in cancer cells. They compete for the ATP binding site of protein tyrosine kinase and reduce tyrosine kinase phosphorylation, thereby inhibiting cancer cell production. So even if the tumour is not getting smaller, its out-of-control growth has been changed. This may give regular chemo for a better chance to work. Slowing or stopping out-of-control growth may also help people live longer, even without adding other drugs. These drugs have made great progress in the treatment of cancer, but the problem of acquired resistance is still unavoidable, restricting the treatment of cancer. Currently, 13 tyrosine kinase inhibitors are approved by Food and Drug Administration. Among them Imatinib, Masitinib, Pazopanib and Toceranib are used for the veterinary purpose Proper dosage regimens, defining of type of cancers and combination with the standard therapeutics are some of the challenges yet to be worked on.

Key words: Receptor Tyrosine Kinases, NRTK, Targeted Therapies, Tyrosine Kinase Inhibitors






Similar Articles

Full-text options


Latest Statistics about COVID-19
• pubstat.org


Add your Article(s) to Indexes
• citeindex.org






Journal Finder
Covid-19 Trends and Statistics
CiteIndex.org
CancerLine
FoodsLine
PhytoMedline
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License (https://creativecommons.org/licenses/by-nc-sa/4.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.